Table 3.
Effects of theophylline (50 mg/kg bw) on heart parameters in rats bearing the Yoshida AH-130 ascites hepatoma
| |
|
Experimental group |
|
|
|
|---|---|---|---|---|---|
| |
C(n = 5) |
T(n = 8) |
T + TPH(n = 9) |
ANOVA |
|
| A | B | ||||
|
LV ejection fraction (%) |
77 ± 2 |
73 ± 2 |
72 ± 3 |
ns |
ns |
|
Fractional shortening (%) |
26 ± 6 |
23 ± 1 |
20 ± 3 |
ns |
ns |
|
LVD dia (mm) |
12 ± 0.1 |
2 ± 0.3 |
11 ± 0.2 |
ns |
ns |
|
LVD sys (mm) |
9 ± 0.7 |
9 ± 0.2 |
10 ± 0.4 |
ns |
ns |
|
PWT dia (mm) |
2.6 ± 0.1 |
2.4 ± 0.1 |
3 ± 0.1 |
ns |
0,012 |
|
PWT sys (mm) |
4 ± 0.2 |
3.2 ± 0.2 |
3.3 ± 0.2 |
0.05 |
ns |
|
LV Vol dia (μl) |
217 ± 22 |
220 ± 14 |
190 ± 17 |
ns |
ns |
|
LV Vol sys (μl) |
50 ± 8 |
55 ± 4 |
48 ± 7 |
ns |
ns |
|
LVSV (μl) |
167 ± 15 |
159 ± 10 |
139 ± 14 |
ns |
ns |
| LVmass (mg) | 313 ± 6 | 274 ± 10 | 322 ± 14 | 0,032 | 0,005 |
Echocardiographic data of non-tumour bearing rats (C), tumour bearing rats (T) and tumour bearing rats treated with theophylline (T + TPH). Results are mean ± SEM. LV ejection fraction: (LV vol dia-LV vol sys)/LV vol dia; fractional shortening: (LVD dia-LVD sys)/LVD sys; Left ventricle diameter in diastole: LVD dia; Left ventricle diameter in systole: LVD sys; posterior wall thickness in diastole: PWT dia; posterior wall thickness in systole: PWT sys; left ventricle volume in diastole: LV Vol dia; left ventricle volume in systole: LV Vol sys; left ventricle stroke volume: LVSV (LV Vol dia- LV Vol sys); left ventricle mass: LV mass (expressed as mg/100 g of initial body weight). Statistical significance of the results by two-way analysis of variance (ANOVA); ns: non-significant differences. A (tumour effect); B (treatment effect).